Local Anesthetic Lidocaine and Cancer: Insight Into Tumor Progression and Recurrence

Zhang, Caihui; Xie, Cuiyu; Lu, Yen‐Shen

doi:10.3389/fonc.2021.669746

Cited by 24 publications

(21 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our studies proved that anti-HBV treatment can attenuate inflammation, decreased the risk of HCC occurrence, and prevent postoperative recurrence of HCC ( 93 , 95 ). Long-term use of non-steroidal anti-inflammatory drugs can also reduce the occurrence and recurrence of cancers ( 123 – 126 ). Targeting cancer stemness- and/or EMT-related signaling pathways might contribute to the eradication of malignant diseases ( 127 – 129 ).…”

Section: Discussionmentioning

confidence: 99%

Cancer Evo–Dev: A Theory of Inflammation-Induced Oncogenesis

Liu

Deng

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Chronic inflammation is a prerequisite for the development of cancers. Here, we present the framework of a novel theory termed as Cancer Evolution-Development (Cancer Evo-Dev) based on the current understanding of inflammation-related carcinogenesis, especially hepatocarcinogenesis induced by chronic infection with hepatitis B virus. The interaction between genetic predispositions and environmental exposures, such as viral infection, maintains chronic non-resolving inflammation. Pollution, metabolic syndrome, physical inactivity, ageing, and adverse psychosocial exposure also increase the risk of cancer via inducing chronic low-grade smoldering inflammation. Under the microenvironment of non-resolving inflammation, pro-inflammatory factors facilitate the generation of somatic mutations and viral mutations by inducing the imbalance between the mutagenic forces such as cytidine deaminases and mutation-correcting forces including uracil–DNA glycosylase. Most cells with somatic mutations and mutated viruses are eliminated in survival competition. Only a small percentage of mutated cells survive, adapt to the hostile environment, retro-differentiate, and function as cancer-initiating cells via altering signaling pathways. These cancer-initiating cells acquire stem-ness, reprogram metabolic patterns, and affect the microenvironment. The carcinogenic process follows the law of “mutation-selection-adaptation”. Chronic physical activity reduces the levels of inflammation via upregulating the activity and numbers of NK cells and lymphocytes and lengthening leukocyte telomere; downregulating proinflammatory cytokines including interleukin-6 and senescent lymphocytes especially in aged population. Anti-inflammation medication reduces the occurrence and recurrence of cancers. Targeting cancer stemness signaling pathways might lead to cancer eradication. Cancer Evo-Dev not only helps understand the mechanisms by which inflammation promotes the development of cancers, but also lays the foundation for effective prophylaxis and targeted therapy of various cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer Evo–Dev: A Theory of Inflammation-Induced Oncogenesis

Liu

Deng

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Local anesthetics (LAs) are a group of small molecule drugs widely used in clinical anesthesia and analgesia. With the widespread involvement of LA in cancer-related surgery, there is growing clinical evidence that the use of LA during or after surgery generally improves patient outcomes [ 68 ]. Studies have shown that LAs can kill tumor cells if they come into direct contact with them [ 69 ].…”

Section: Cutaneous Melanomamentioning

confidence: 99%

Advances in the Application of Nanomaterials to the Treatment of Melanoma

Wang

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Melanoma can be divided into cutaneous melanoma, uveal melanoma, mucosal melanoma, etc. It is a very aggressive tumor that is prone to metastasis. Patients with metastatic melanoma have a poor prognosis and shorter survival. Although current melanoma treatments have been dramatically improved, there are still many problems such as systemic toxicity and the off-target effects of drugs. The use of nanoparticles may overcome some inadequacies of current melanoma treatments. In this review, we summarize the limitations of current therapies for cutaneous melanoma, uveal melanoma, and mucosal melanoma, as well as the adjunct role of nanoparticles in different treatment modalities. We suggest that nanomaterials may have an effective intervention in melanoma treatment in the future.

show abstract

“…In breast cancer surgery LIDO contributes to prevent both acute and chronic pain after breast cancer surgery ( Grigoras et al, 2012 ). And it was shown to have anticancer properties ( Chamaraux-Tran and Piegeler, 2017 ; Chamaraux-Tran et al, 2018 ; Wall and Buggy, 2021 ; Zhang et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Metabolomic Impact of Lidocaine on a Triple Negative Breast Cancer Cell Line

et al. 2022

View full text Add to dashboard Cite

Background: Metabolomics and onco-anesthesia are two emerging research fields in oncology. Metabolomics (metabolites analysis) is a new diagnostic and prognostic tool that can also be used for predicting the therapeutic or toxic responses to anticancer treatments. Onco-anesthesia studies assess the impact of anesthesia on disease-free and overall survival after cancer surgery. It has been shown that local anesthetics (LA), particularly lidocaine (LIDO), exert antitumor properties both in vitro and in vivo and may alter the biologic fingerprints of cancer cells. As LA are known to impair mitochondrial bioenergetics and byproducts, the aim of the present study was to assess the impact of LIDO on metabolomic profile of a breast cancer cell line.Methods: Breast cancer MDA-MB-231 cells were exposed for 4 h to 0.5 mM LIDO or vehicle (n = 4). The metabolomic fingerprint was characterized by high resolution magic angle spinning NMR spectroscopy (HRMAS). The multivariate technique using the Algorithm to Determine Expected Metabolite Level Alteration (ADEMA) (Cicek et al., PLoS Comput. Biol., 2013, 9, e1002859), based on mutual information to identify expected metabolite level changes with respect to a specific condition, was used to determine the metabolites variations caused by LIDO.Results: LIDO modulates cell metabolites levels. Several pathways, including glutaminolysis, choline, phosphocholine and total choline syntheses were significantly downregulated in the LIDO group.Discussion: This is the first study assessing the impact of LIDO on metabolomic fingerprint of breast cancer cells. Among pathways downregulated by LIDO, many metabolites are reported to be associated with adverse prognosis when present at a high titer in breast cancer patients. These results fit with the antitumor properties of LIDO and suggest its impact on metabolomics profile of cancer cells. These effects of LIDO are of clinical significance because it is widely used for local anesthesia with cutaneous infiltration during percutaneous tumor biopsy. Future in vitro and preclinical studies are necessary to assess whether metabolomics analysis requires modification of local anesthetic techniques during tumor biopsy.

show abstract

Local Anesthetic Lidocaine and Cancer: Insight Into Tumor Progression and Recurrence

Cited by 24 publications

References 130 publications

Cancer Evo–Dev: A Theory of Inflammation-Induced Oncogenesis

Cancer Evo–Dev: A Theory of Inflammation-Induced Oncogenesis

Advances in the Application of Nanomaterials to the Treatment of Melanoma

Metabolomic Impact of Lidocaine on a Triple Negative Breast Cancer Cell Line

Contact Info

Product

Resources

About